Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer

Prostate cancer continues to be the most common lethal malignancy diagnosed in American men and the second leading cause of male cancer mortality. The American Cancer Society estimates that during 2005, ∼232,090 new cases of prostate cancer will be diagnosed in the United States and 30,350 men

[1]  H. Scher,et al.  Collocation of androgen receptor gene mutations in prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  K. Grigor,et al.  Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer , 2003, British Journal of Cancer.

[3]  J. Sloan,et al.  Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Balk,et al.  Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence , 2004, Journal of cellular biochemistry.

[5]  P. Ell,et al.  Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. , 2004, Urology.

[6]  D. Chopin,et al.  Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. , 1993, The American journal of pathology.

[7]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[8]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[9]  O. Jänne,et al.  Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. , 2004, Molecular endocrinology.

[10]  R L Vessella,et al.  Advances in Brief Amplification and Overexpression of Androgen Receptor Gene in Hormone-Refractory Prostate Cancer 1 , 2001 .

[11]  C. Huggins.  Endocrine-induced regression of cancers. , 1967, American journal of surgery.

[12]  F. S. French,et al.  A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. , 2001, Cancer research.

[13]  M. Harada,et al.  Analysis of bone metastasis of prostatic adenocarcinoma in 137 autopsy cases. , 1992, Advances in experimental medicine and biology.

[14]  N. Maitland,et al.  Prospective identification of tumorigenic prostate cancer stem cells. , 2005, Cancer research.

[15]  H. Perlman,et al.  Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. , 1995, Cancer research.

[16]  E. Latulippe,et al.  Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. , 2004, The American journal of pathology.

[17]  S. Berry,et al.  Re: A Randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2004, Journal of the National Cancer Institute.

[18]  E. Zuhowski,et al.  Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with Refractory Advanced Cancers , 2005, Clinical Cancer Research.

[19]  S. Lakhani,et al.  Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Donna M. Peehl,et al.  Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor , 2000, Nature Medicine.

[21]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[22]  Mark F McCarty,et al.  Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy , 2004, Integrative cancer therapies.

[23]  Daniel Gioeli,et al.  Ras signaling in prostate cancer progression , 2004, Journal of cellular biochemistry.

[24]  R A Rifkind,et al.  Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. , 2000, Cancer research.

[25]  M. Campbell,et al.  Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. , 1992, Cancer research.

[26]  H. Klocker,et al.  The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. , 2003, The American journal of pathology.

[27]  R. Dreicer,et al.  Novel cytotoxic and biological agents for prostate cancer: where will the money be in 2005? , 2005, European journal of cancer.

[28]  G. Buchanan,et al.  Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  P. Kantoff,et al.  Symposium on Androgen Action in Prostate Cancer , 2004, Cancer Research.

[30]  M. Gleave,et al.  Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer , 2005, World Journal of Urology.

[31]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[32]  L. Grochow,et al.  Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  I. Tannock,et al.  Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. , 2005, Cancer research.

[34]  E. Scholar,et al.  Role of Tyrosine Kinase Inhibitors in Cancer Therapy , 2005, Journal of Pharmacology and Experimental Therapeutics.

[35]  M. Egorin,et al.  Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer , 2003 .

[36]  J. Bosch,et al.  Biochemical Parameters, Nutritional Status and Efficiency of Dialysis in CAPD and CCPD Patients , 1999, American Journal of Nephrology.

[37]  C. Logothetis,et al.  Osteoblasts in prostate cancer metastasis to bone , 2005, Nature Reviews Cancer.

[38]  Shaomeng Wang,et al.  (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. , 2005, Molecular cancer therapeutics.

[39]  O. Jänne,et al.  Androgen-receptor-interacting nuclear proteins. , 2000, Biochemical Society transactions.

[40]  F. S. French,et al.  Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. , 2001, Cancer research.

[41]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[42]  J. Manola,et al.  Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Hubert Vesselle,et al.  Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. , 2003, Human pathology.

[44]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.

[45]  S. Larson,et al.  Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer , 2007, Clinical Cancer Research.

[46]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[47]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. , 2002, The Journal of urology.

[48]  G. Jenster,et al.  The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens , 1992, Journal of Steroid Biochemistry and Molecular Biology.

[49]  P. Hershberger,et al.  Anti-tumor activity of calcitriol: pre-clinical and clinical studies , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[50]  J. Crook,et al.  Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. , 1993, International journal of radiation oncology, biology, physics.

[51]  M. Gleave,et al.  A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer , 2005, Clinical Cancer Research.

[52]  F. Labrie,et al.  Treatment of prostate cancer with gonadotropin-releasing hormone agonists. , 1986, Endocrine reviews.

[53]  Chawnshang Chang,et al.  Androgen receptor corepressors: An overview , 2005, The Prostate.

[54]  K. Pienta,et al.  Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  J. Kozlowski,et al.  Carcinoma of the prostate. Hormonal therapy , 1987, Cancer.

[56]  Liang Xia,et al.  Functional analysis of 44 mutant androgen receptors from human prostate cancer. , 2002, Cancer research.

[57]  M. Tsai,et al.  Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer , 2003, Oncogene.

[58]  T. Guthrie,et al.  Prostate cancer. , 2020, American family physician.

[59]  P. Kantoff,et al.  Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Georg Bartsch,et al.  Interleukin‐6 regulation of prostate cancer cell growth , 2005, Journal of cellular biochemistry.

[61]  D. Tindall,et al.  p300 in prostate cancer proliferation and progression. , 2003, Cancer research.

[62]  G. Kao,et al.  Mitotic spindle checkpoint inactivation by trichostatin A defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents , 2005, Cancer biology & therapy.

[63]  C. Schofield,et al.  The HIF pathway as a therapeutic target. , 2004, Drug discovery today.

[64]  S. Inui,et al.  Cloning and Characterization of Androgen Receptor Coactivator, ARA55, in Human Prostate* , 1999, The Journal of Biological Chemistry.

[65]  M. Chen,et al.  Aberrant response in vitro of hormone‐responsive prostate cancer cells to antiandrogens , 1989, The Prostate.

[66]  S. Chan,et al.  Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer , 2004, British Journal of Cancer.

[67]  John Calvin Reed,et al.  Expression of bcl-2 and the progression of human and rodent prostatic cancers. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[68]  I Judson,et al.  Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer , 2004, British Journal of Cancer.

[69]  J Isola,et al.  Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. , 1997, Cancer research.

[70]  Rakesh K Jain,et al.  Antiangiogenic therapy for cancer: current and emerging concepts. , 2005, Oncology.

[71]  D. McDonnell,et al.  Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display. , 2005, Molecular endocrinology.

[72]  K. Wood,et al.  Antitumor activity of a kinesin inhibitor. , 2004, Cancer research.

[73]  F. Saad,et al.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. , 2004, Journal of the National Cancer Institute.

[74]  M. Hida,et al.  Metastatic patterns of prostatic cancer: Correlation between sites and number of organs involved , 1984, Cancer.

[75]  David C. Smith,et al.  Advances in Prostate Cancer Chemotherapy: A New Era Begins 1 , 2005, CA: a cancer journal for clinicians.

[76]  A. Jimeno,et al.  Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer , 2005, Expert review of anticancer therapy.

[77]  H. Scher,et al.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  Shankar Vallabhajosula,et al.  Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  D. Tindall,et al.  Mechanisms of androgen-refractory prostate cancer. , 2004, The New England journal of medicine.

[80]  M. Egorin,et al.  Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  R. Gittes.  Carcinoma of the prostate. , 1991, The New England journal of medicine.

[82]  H. Moch,et al.  Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. , 2000, Human pathology.

[83]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[84]  D. Ghosh,et al.  Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases , 2004, Cancer Research.

[85]  K. Pienta,et al.  The "emigration, migration, and immigration"of prostate cancer. , 2005, Clinical prostate cancer.

[86]  J. Eastham,et al.  Androgen receptor mutations in prostate cancer. , 2000, Cancer research.

[87]  E. Gelmann,et al.  Molecular biology of the androgen receptor. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  H. Klocker,et al.  Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides , 2000, Cancer Gene Therapy.

[89]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[90]  Xin Yu,et al.  Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. , 2002, The American journal of pathology.

[91]  M. Pike,et al.  A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. , 1997, Cancer research.

[92]  S. Vuk-Pavlović,et al.  Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen‐independent prostate cancer: A phase 2 trial , 2004, The Prostate.

[93]  O. Cussenot,et al.  Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. , 2001, Cancer research.

[94]  D. Toft,et al.  Effect of geldanamycin on androgen receptor function and stability , 2002, Cell stress & chaperones.

[95]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[96]  Noah Craft,et al.  A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.

[97]  F. Marshall,et al.  Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies , 2000, Cancer Chemotherapy and Pharmacology.

[98]  Erwin G. Van Meir,et al.  Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. , 2002, Cancer research.